natgillin/translations-raw huggingface dataset:
These APAs will specify a number of details with respect to expected payments (such as payment amounts, schedule and financial structure), delivery details of the vaccine if and when successful (such as price per person vaccinated, quantity of vaccines and delivery timeline after approval) and any other relevant conditions (such as production capacity in the EU, possible availability of production facilities for the manufacturing of other vaccines or medicines in case of failure, or liability arrangements). 
V sporazumih za vnaprejšnji nakup bodo določene podrobnosti glede pričakovanih plačil (kot so zneski plačil, časovni okvir in finančna struktura), podrobnosti o dobavi cepiva, če in ko bo cepivo uspešno (kot so cena cepiva na osebo, količina cepiv in časovni okvir dobave po odobritvi), in vsi drugi zadevni pogoji (kot so proizvodne zmogljivosti v EU, morebitna razpoložljivost proizvodnih zmogljivosti za proizvodnjo drugih cepiv ali zdravil v primeru neuspeha ter ureditve glede odgovornosti).
In response to the WHO's call for global action on 24 April, the Commission launched a Global Coronavirus Response to mobilise resources and join forces among countries and global health organisations to accelerate the development and deployment of diagnostics, therapeutics and vaccines wherever they are needed. 
V odgovor na poziv STO 24. aprila k ukrepanju na svetovni ravni je Komisija organizirala vrh o globalnem odzivu na koronavirus, da bi mobilizirala vire in združila moči med državami in zdravstvenimi organizacijami po svetu, da bi pospešila razvoj in uvajanje diagnostike, zdravljenja in cepiv, kjer koli so potrebni.
The Commission stands ready to enter into negotiations with all vaccine producers, which have either started or have firm plans to start clinical trials still in 2020 and which have the potential to deliver doses at the necessary scale and within the necessary timelines. 
Komisija je pripravljena začeti pogajanja z vsemi proizvajalci cepiv, ki so se že začeli klinična preskušanja ali imajo zanje trdne načrte še v letu 2020, in ki bi lahko zagotovili odmerke v potrebnem obsegu in v potrebnih časovnih okvirih.
The Commission will implement the EU strategy for COVID-19 vaccines together with the Member States, thus increasing the likelihood that all who need vaccines will have equitable and affordable access to the supplies of these vaccines in the shortest possible time frame. 
Komisija bo strategijo EU za cepiva proti COVID-19 izvajala skupaj z državami članicami, s čimer bo povečala verjetnost, da bodo imeli vsi, ki cepiva potrebujejo, pravičen in cenovno dostopen dostop do zalog teh cepiv v najkrajšem možnem časovnem okviru.
To this end, the EU is leading the global effort for universal testing, treatment and vaccination by mobilising resources through international pledging and by joining forces with countries and global health organisations through the Access to Covid-19 Tools (ACT) Accelerator collaborative framework 1 . 
V ta namen EU vodi globalna prizadevanja za univerzalno testiranje, zdravljenje in cepljenje z mobilizacijo sredstev prek mednarodnih donacij ter z združevanjem moči z državami in svetovnimi zdravstvenimi organizacijami prek okvira sodelovanja Pospeševalnik ACT (za dostop do orodij COVID-19) 1 .
When any of the vaccines becomes available, Member States can use the results of the procurement carried out by the Commission to acquire vaccines directly from the producer, without the need to carry out an additional national procurement procedure. 
Ko bo katero od cepiv na voljo, lahko države članice uporabijo rezultate javnega naročila, ki ga izvede Komisija, za nakup cepiv neposredno od proizvajalca, ne da bi jim bilo pri tem treba izvesti dodaten nacionalni postopek javnega naročanja.
Through the ETF, it provides rapid scientific advice and feedback on development plans, offers scientific support to facilitate clinical trials conducted in the EU and a rolling review of incoming scientific data from clinical trials to allow for an accelerated assessment of the final data after completion of the clinical trials. 
Prek te projektne skupine zagotavlja hitro znanstveno svetovanje in povratne informacije o načrtih razvoja ter nudi znanstveno podporo za olajšanje kliničnih preskušanj, ki se izvajajo v EU, in redno pregledovanje vhodnih znanstvenih podatkov iz kliničnih preskušanj, da se omogoči pospešeno ocenjevanje končnih podatkov po zaključku kliničnih preskušanj.
As per the requirements of the ESI Regulation, the Member States and the Commission would agree in the above-mentioned agreement that the Commission carries out the procurement on behalf of the Member States including the terms applicable to such procurement. 
V skladu z zahtevami iz uredbe o ESI bi se države članice in Komisija v navedenem sporazumu strinjale, da Komisija izvede javno naročilo v imenu držav članic, vključno z določitvijo pogojev, ki se uporabijo za tako javno naročilo.
In addition, the Commission has adopted alongside the present Communication a proposal for a Regulation to adjust and clarify certain legal requirements for the environmental risk assessment for COVID-19 vaccines that contain or consist of genetically modified organisms that could otherwise slow down the conduct of clinical trials with these vaccines in the EU and their administration, where appropriate, to specific populations that could benefit from early access. 
Poleg tega je Komisija skupaj s tem sporočilom sprejela predlog uredbe za prilagoditev in pojasnitev določenih pravnih zahtev za oceno tveganja za okolje za cepiva proti COVID-19, ki vsebujejo gensko spremenjene organizme ali so iz njih sestavljena, ki bi lahko drugače upočasnile izvajanje kliničnih preskušanj s temi cepivi v EU ter njihovo uporabo, kadar je to primerno, za določeno skupino prebivalstva, ki bi lahko imela koristi od zgodnjega dostopa.
The Commission will propose to Member States to alleviate the language requirements and to ensure the acceptability of multi-dose presentations for COVID-19 vaccines to facilitate more rapid deployment of a new vaccine and more even distribution of the doses between Member States. 
Komisija bo državam članicam predlagala, naj ublažijo jezikovne zahteve in zagotovijo sprejemljivost pakiranja z večkratnimi odmerki za cepiva proti COVID-19, da bi se omogočilo hitrejše uvajanje novega cepiva in enakomernejša distribucija odmerkov med državami članicami.
Delivering such an undertaking within such a compressed timeframe requires running clinical trials in parallel with investing in production capacity and securing raw materials so that production can start as soon as those trials are concluded, or even earlier. 
Da bi to dosegli v tako omejenem časovnem okviru, je treba klinična preskušanja izvajati vzporedno z naložbami v proizvodne zmogljivosti in zagotavljanjem surovin, da se bo proizvodnja lahko začela takoj, ko se bodo navedena preskušanja zaključila, ali celo prej.
In the light of the experience it will gain with the present strategy, and building on existing international procurement initiatives, the Commission is ready to support the development and operation of an inclusive international COVID-19 procurement mechanism that facilitates early and affordable access to vaccines and other tools for all who need it across the world. 
Komisija je glede na izkušnje, ki jih bo pridobila s to strategijo, in na podlagi obstoječih mednarodnih pobud za javna naročila pripravljena podpreti razvoj in delovanje vključujočega mednarodnega mehanizma za javna naročila v zvezi s COVID-19, ki bi omogočil zgodnji in cenovno dostopen dostop do cepiv in drugih orodij za vse, ki jih potrebujejo, po vsem svetu.
This alliance was formed to pool the national resources of those countries and secure fair access to vaccine supplies for the European population. 
Njegov namen je združiti nacionalna sredstva navedenih držav in zagotoviti pravičen dostop evropskega prebivalstva do zalog cepiva.
If additional funds are needed, Member States will have the possibility to top-up the ESI to make up any financing gap in order to finance more offers. 
Če bodo potrebna dodatna sredstva, bodo imele države članice možnost, da za zapolnitev morebitne finančne vrzeli namenijo dodatna finančna sredstva v instrument ESI za financiranje več ponudb.
This is particularly the case for the Horizon 2020 InnovFin Infectious Disease Finance Facility (H2020 InnovFin IDFF), a debt facility guaranteed at 100% by the Commission, which provides support from clinical studies to scaled-up manufacturing. 
To zlasti velja za finančni instrument za nalezljive bolezni v programu InnovFin v okviru programa Obzorje 2020 (H2020 InnovFin IDFF), ki je dolžniška shema, za katero Komisija jamči 100 %, ki zagotavlja podporo od kliničnih študij do proizvodnje v velikem obsegu.
Under normal circumstances, companies make investments in production capacity dependent on the probability of obtaining a successful vaccine from the development phase that will meet the strict standards of quality, safety and efficacy needed to be authorised, and that will be viable according to the demand projections available. 
V običajnih okoliščinah podjetja od razvojne faze dalje vlagajo v proizvodne zmogljivosti glede na verjetnost pridobitve uspešnega cepiva, ki izpolnjuje stroge standarde kakovosti, varnosti in učinkovitosti, potrebne za njegovo odobritev, in ki bo poslovno vzdržno glede na razpoložljive projekcije povpraševanja.
Supporting and accelerating clinical trials and de-risking simultaneous investments in production capacity will significantly increase the potential for the world to have access to an affordable vaccine sooner than would otherwise be the case. 
S podpiranjem in pospeševanjem kliničnih preskušanj in zmanjševanjem tveganja sočasnih naložb v proizvodne zmogljivosti se bodo znatno povečale možnosti, da dobi svet dostop do cenovno dostopnega cepiva prej, kot bi ga sicer.
The need to deliver quickly, the high upfront costs, and the high failure rate make investing in a COVID-19 vaccine a high-risk decision for vaccine developers. 
Zaradi nujnosti hitrega razvoja, visokih začetnih stroškov in visoke stopnje neuspeha je vlaganje v cepivo proti COVID-19 zelo tvegana odločitev za razvijalce cepiva.
In order to maximise the chances of success, the most promising candidates should be supported in their development and in the building-up of manufacturing capacity. 
Da bi čim bolj povečali možnosti za uspeh, bi morali podpreti razvoj in vzpostavljanje proizvodnih zmogljivosti za najobetavnejše kandidate.
Compliance with good manufacturing practice in the manufacture or importation of investigational medicinal products containing or consisting of GMOs for use in clinical trials will continue to be mandatory, and an environmental risk assessment of the products will be carried out before a marketing authorisation is granted in the EU. 
Izvajanje dobre proizvodne prakse pri proizvodnji ali uvozu zdravil v preskušanju, ki vsebujejo GSO ali so iz njih sestavljena, za uporabo v kliničnih preskušanjih bo še naprej obvezno, preden se dodeli dovoljenje za promet v EU, pa se bo za zdravila izvedla ocena tveganja za okolje.
They will de-risk the necessary investments related to both vaccine development and clinical trials, and the preparation of the at-scale production capacity along the entire vaccine production chain which is required for a rapid deployment of sufficient doses of an eventual vaccine in the EU and globally. 
Zmanjšali bodo tveganja nujnih naložb, povezanih z razvojem cepiva in kliničnim preskušanjem, kot tudi tveganja priprave ustreznih proizvodnih zmogljivosti v celotni proizvodni verigi za cepivo, potrebnih za hitro uvajanje zadostnih odmerkov morebitnega cepiva v EU in po svetu.
However, a vaccine against COVID-19 is needed more urgently than this. 
Vendar cepivo proti COVID-19 nujno potrebujemo prej.
Once any of the vaccines supported proves successful, Member States will be able to acquire that vaccine directly from the producer on the basis of the conditions laid down in the APA. 
Ko se bo katero od podprtih cepiv izkazalo za uspešno, bodo lahko države članice navedeno cepivo kupile neposredno pri proizvajalcu na podlagi pogojev, določenih v sporazumu za vnaprejšnji nakup.
There is considerable variety across Member States in the national requirements and procedures implementing the GMO Directives used to assess environmental risks of clinical trials of medicinal products that contain or consist of GMOs. 
Nacionalne zahteve in postopki za izvajanje direktiv o GSO, ki se uporabljajo za ocenjevanje okoljskih tveganj kliničnih preskušanj zdravil, ki vsebujejo GSO ali so iz njih sestavljena, se med državami članicami zelo razlikujejo.
A joint negotiation team composed of the Commission and a small number of Member State experts will negotiate the APAs. 
O sporazumu za vnaprejšnji nakup se bo pogajala skupna pogajalska ekipa, sestavljena iz predstavnikov Komisije in majhnega števila strokovnjakov iz držav članic.
While the Commission will be responsible for the procurement process and the APA contracts concluded, the liability for the deployment and use of the vaccine, including any specific indemnification required by a given APA will remain with the purchasing Member States. 
Medtem ko bo Komisija odgovorna za postopek javnega naročanja in sklenitev pogodb v zvezi s sporazumom za vnaprejšnji nakup, bodo imele odgovornost za uvajanje in uporabo cepiva, vključno z morebitnimi posebnimi odškodninami, ki se bodo zahtevale v posameznem sporazumu za vnaprejšnji nakup, še naprej države članice, ki bodo cepivo kupile.
The related funding will come from the ESI. 
Ustrezna finančna sredstva bo zagotovil instrument ESI.
The APAs will be concluded on behalf of all participating Member States. 
Sporazum za vnaprejšnji nakup bo sklenjen v imenu vseh sodelujočih držav članic.
A common approach to the development of vaccines is based on attenuated viruses and viral vectors. 
Skupni pristop k razvoju cepiv temelji na atenuiranih virusih in virusnih vektorjih, ki prejemnikom cepiva zagotavljajo odpornost, niso pa patogeni.
In addition to it being in their clear self-interest to do so, high-income countries have a responsibility to accelerate the development and production of a safe and effective vaccine and make it accessible for all the regions of the world. 
Države z visokim dohodkom so odgovorne, da pospešijo razvoj in proizvodnjo varnega in učinkovitega cepiva ter ga dajo na voljo vsem regijam sveta, pri čemer je to jasno tudi v njihovem lastnem interesu.
However, the quest for a vaccine against COVID-19 is particularly challenging due to the urgency. 
Vendar je zaradi nujnosti situacije iskanje cepiva proti COVID-19 še posebej zahtevno.
A permanent solution to this crisis is most likely to be brought about by the development and deployment of an effective and safe vaccine against the virus. 
Zelo verjetno je, da bosta razvoj in uvajanje učinkovitega in varnega cepiva proti virusu prinesla trajno rešitev za to krizo.
The mobilised funds serve to empower and resource existing organisations such as CEPI (the Coalition for Epidemic Preparedness Innovation) and GAVI, the vaccine alliance, to work together in partnership with industry, science, regulators and foundations as part of the ACT-Accelerator. 
Mobilizirana sredstva so namenjena krepitvi vloge in virov obstoječih organizacij, kot sta CEPI (koalicija za inovacije na področju pripravljenosti na epidemije) in GAVI (Svetovna zveza za cepiva in imunizacijo), da sodelujejo v partnerstvu z industrijo, znanostjo, regulativnimi organi in fundacijami v okviru Pospeševalnika ACT. Pospeševalnik ACT je namenski okvir, ki ga je Komisija pomagala vzpostaviti za okrepitev globalnega sodelovanja pri pospeševanju razvoja in univerzalnega uvajanja orodij, potrebnih za boj proti COVID-19.
-Coverage of different technologies: vaccines are being developed using a number of different types of platforms/production methods 4 . 
-pokritost z različnimi tehnologijami: razvoj cepiv poteka z uporabo številnih različnih vrst platform/načinov proizvodnje 4 , Da bi čim bolj povečali možnosti za razvoj učinkovitega in varnega cepiva, bi moral nabor sporazumov za vnaprejšnji nakup zajemati različne tehnologije,
Compliance in general still appears to be low. 
Skladnost se na splošno še vedno zdi nizka.
Member States must put more focus on control and enforcement. 
Države članice se morajo bolj osredotočiti na nadzor in izvrševanje.
The Commission will fully implement management plans. 
Komisija bo v celoti izvajala načrte upravljanja.
2.Progress in achieving Fmsy 1 
2.Napredek pri doseganju Fmsy 1
Planned work Schedule 21 22 
Predvideni urnik dela 21 22
The swap mechanism was used successfully. 
Mehanizem zamenjave je bil uspešno uporabljen.
The Commission intends to cover as many stocks as possible in its initial proposals. 
Komisija namerava v svojih začetnih predlogih zajeti čim več staležev.
It is equally important for the fisheries sector's recovery. 
Pomembno je tudi za okrevanje ribiškega sektorja.
The number of vessels in the EU fleet continued to decrease. 
Število plovil v floti EU se je še naprej zmanjševalo.
This means that fishing has steadily become more sustainable. 
To pomeni, da je ribolov postopoma postal bolj trajnosten.
The significant achievements of the common fisheries policy during the past decade show the direction to pursue in the future. 
Pomembni dosežki skupne ribiške politike v zadnjem desetletju kažejo pot, ki ji je treba slediti v prihodnosti.
These measures will help to protect thousands of jobs in the EU's coastal regions and maintain food security. 
Ti ukrepi bodo pripomogli k zaščiti tisočih delovnih mest v obalnih regijah EU in ohranitvi prehranske varnosti.
The Commission supported the use of these measures in its proposal for a revised fisheries control system, currently under discussion by the Council and the European Parliament. 
Komisija je podprla uporabo teh ukrepov v svojem predlogu za revidiran sistem za nadzor ribištva, o katerem trenutno razpravljata Svet in Evropski parlament.
(9) Information is available on the website of the European Market Observatory for Fisheries and Aquaculture Products (EUMOFA) at https://www.eumofa.eu . 
(9) Informacije so na voljo na spletni strani Evropske opazovalnice trgov za proizvode iz ribištva in akvakulture (EUMOFA) https://www.eumofa.eu .
(11) The report from Lithuania was received but due to transmission issues was not part of the assessment. 
(11) Poročilo Litve je bilo prejeto, vendar zaradi težav s prenosom ni bilo vključeno v oceno.
(7) 2003 is used by the STECF as reference year as this is when the data series starts. 
(7) STECF uporablja leto 2003 kot referenčno leto, saj se takrat začnejo serije podatkov.
Control of the landing obligation remains a challenge that has not been resolved 13 . 
Nadzor obveznosti iztovarjanja ostaja nerešen izziv 13 .
The transition period set out in the EU-United Kingdom withdrawal agreement expires at the end of 2020, unless extended. 
Prehodno obdobje, določeno v sporazumu o izstopu Združenega kraljestva iz EU, se izteče konec leta 2020, razen če se podaljša.
To tackle this unprecedented situation, the Commission proposed a range of urgent relief measures, which the EU's legislators approved. 
Za obvladovanje teh razmer brez primere je Komisija predlagala vrsto nujnih ukrepov pomoči, ki sta jih odobrila zakonodajalca EU.
The large pelagic stocks receive advice in September. 
Mnenja o velikih pelagičnih staležih bodo na voljo septembra.
The Commission will continue working with the co-legislators to reach an agreement on the revised fisheries control system 15 , which can facilitate the use of these modern control tools. 
Komisija bo še naprej sodelovala s sozakonodajalcema, da bi dosegla dogovor o revidiranem sistemu za nadzor ribištva 15 , ki lahko olajša uporabo teh sodobnih nadzornih orodij.
Significantly fewer Member States have carried out specific studies and pilot projects to test selective gear or avoidance strategies. 
Znatno manj držav članic je izvedlo posebne študije in pilotne projekte za preskušanje selektivnih orodij ali strategij izogibanja.
Since mid-April, the situation seems to be improving both for the catching and fish processing sector 9 . 
Zdi se, da se od sredine aprila razmere izboljšujejo, in sicer tako v sektorju ribolova kot v sektorju predelave rib 9 .
Furthermore, fishing fleets depending on export markets were highly impacted. 
Poleg tega so bile močno prizadete ribiške flote, ki so odvisne od izvoznih trgov.
2.3.The landing obligation 10 
2.3.Obveznost iztovarjanja 10
Art. 13, 14 and 15 in Council Regulation (EU) 2020/123. 
Členi 13, 14 in 15 Uredbe Sveta (EU) 2020/123.
At the moment, it is not yet known how long the lockdown period will last and by how much quotas will be under-utilised. 
Trenutno še ni znano, kako dolgo bo obdobje zapore trajalo in v kolikšni meri bodo kvote premalo izkoriščene.
The obligation to land all catches entered fully into force in 2019. 
Obveznost iztovarjanja celotnega ulova je začela v celoti veljati leta 2019.
The average annual FTE wage is EUR 25 000. 
Povprečna letna plača na ekvivalent polnega delovnega časa znaša 25 000 EUR.
Continuous efforts are needed to increase the selectivity in fishing gear and techniques. 
Potrebna so stalna prizadevanja za povečanje selektivnosti ribolovnega orodja in tehnik.
The Council set 62 out of 78 TACs in line with Fmsy. 
Svet je določil 62 od 78 TAC v skladu s Fmsy.
The situation in the Mediterranean and Black Seas remains a cause for concern, and further concerted efforts are required. 
Razmere v Sredozemskem in Črnem morju so še vedno zaskrbljujoče, zato je potrebno nadaljnje usklajeno delovanje.
Council meeting on the fishing opportunities proposal for the Atlantic/North Sea 
Seja Sveta o predlogu o ribolovnih možnostih za Atlantik / Severno morje
The Commission invites Member States and stakeholders to consider the scientific advice as soon as it becomes publicly available 18 . 
Komisija poziva države članice in deležnike, naj upoštevajo znanstveno mnenje, takoj ko bo javno dostopno 18 .
Stakeholders will also have the opportunity to make recommendations on fishing opportunities through their respective advisory councils and Member States. 
Deležniki bodo imeli tudi možnost dati priporočila o ribolovnih možnostih prek svojih zadevnih svetovalnih svetov in držav članic.
Therefore, it is expected that in 2020 more than 99% of landings in the Baltic, North Sea and the Atlantic managed exclusively by the EU will come from sustainably managed fisheries. 
Zato se pričakuje, da bo leta 2020 več kot 99 % iztovarjanj v Baltskem in Severnem morju ter Atlantiku, ki jih upravlja izključno EU, izhajalo iz trajnostno upravljanega ribolova.
After 2014, however, the indicator shows an increasing number of stocks exploited above Fmsy 5 . 
Po letu 2014 pa kazalnik kaže vedno večje število staležev, ki se izkoriščajo nad Fmsy 5 .
Any further flexibility will be assessed in the light of the existing legal framework and the common fisheries policy objectives as confirmed on the basis of the best available scientific advice.. 
Kakršna koli dodatna prilagodljivost se bo ocenila glede na obstoječi pravni okvir in skupne cilje ribiške politike, kot so bili potrjeni na podlagi najboljšega razpoložljivega znanstvenega mnenja.
In addition to the problems of demand, sanitary measures hampered some fisheries. 
Poleg težav v zvezi s povpraševanjem so nekatere vrste ribolova ovirali tudi sanitarni ukrepi.
The Scientific, Technical and Economic Committee for Fisheries (STECF) notes, however, the large uncertainty surrounding this indicator. 
Vendar Znanstveni, tehnični in gospodarski odbor za ribištvo (STECF) ugotavlja, da je za ta kazalnik značilna velika negotovost.
A new temporary framework for State aid enables Member States to provide relief in the form of State aid to economic operators active in the fisheries sector and hit by the crisis. 
V novem začasnem okviru državne pomoči lahko države članice nudijo podporo v obliki državne pomoči gospodarskim subjektom, dejavnim v ribiškem sektorju, ki jih je prizadela kriza.